Bird & Bird represents CureVac in lawsuit against BioNTech

Contacts

natalie ackermann Module
Dr. Natalie Ackermann-Blome

Associate
Germany

As an associate in our Inellectual Property Group, I advise domestic and international clients on all matters of Intellectual Property Law with a particular focus on patents, utility models and trade secrets.

oliver jan juengst module
Oliver Jan Jüngst, LL.M.

Partner
Germany

I have been with our firm since the opening of its first German office in Düsseldorf in 2002. I have 20 years' history of litigating patents on both sides of the "v."

International law firm Bird & Bird represents CureVac SE in its lawsuit against BioNTech SE for patent and utility model infringement.

CureVac is the owner of numerous property rights in the field of molecular biology and biotechnology. Among other things, it is the owner of patent and utility model rights that become virulent in the development and production of drugs and vaccines based on the messenger molecule messenger RNA (mRNA) (EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1, DE 20 2015 009 974 U1 and EP 3 708 668 B1). A technique based on the messenger molecule mRNA was used, among other things, in the field of the development and production of vaccines in the context of the coronavirus pandemic.

BioNTech markets vaccines in Germany under the name "Comirnaty - Tozinameran, COVID-19 mRNA vaccine (nucleoside-modified)". In CureVac's view, these vaccines implement the teaching of its patents-in-suit or utility models. It is therefore challenging this infringement by way of a step action with the aim of claiming damages.

The first stage was heard on 15 August 2023 before the 4c. Patent Chamber of the Düsseldorf District Court (file no.: 4c O 38/22, 4c O 46/22, 4c O 47/22, 4c O 48/22 and 4c O 51/22). CureVac demands information and accounting from BioNTech about the extent to which they use or have used modified mRNA in this sense for the production of a vaccine for vaccination against viral infectious diseases, using the technical teaching protected by CureVac.

The chamber has set the date for a decision to be announced on the 28th of December 2023 in view of a hearing before the Federal Patent Court on the invalidity action, which is scheduled for the 19th of December  2023. In the other proceedings, the date for pronouncing a decision was set for the 28th of September 2023.

CureVac SE was advised by the following Bird & Bird lawyers: partner Oliver Jan Jüngst, LL.M. (lead) and associate Dr. Natalie Ackermann-Blome, both IP Litigation, Düsseldorf.

News & Deals

More News & Deals
News Bird & Bird opening office in Riyadh, Saudi Arabia

May 20 2025

Read More
Deal Bird & Bird advises MirSense on its €7 million fundraising

May 19 2025

Read More
News Bird & Bird named most active clean energy legal adviser in the Clean Energy League Table 2025

May 19 2025

Read More
Deal Bird & Bird Advises Voyc on $2 Million Seed Funding Round

May 14 2025

Read More
Deal Bird & Bird advises Contour Design on acquisition of Active Key business from Cherry SE

May 13 2025

Read More
Deal Bird & Bird advised Entegra on the acquisition of Agap’pro

May 13 2025

Read More